Description

SMS Pharmaceuticals Ltd lists 50 lakh new equity shares issued to promoters on preferential basis pursuant to warrant conversion, with lock-in period until October 2027.

Summary

SMS Pharmaceuticals Ltd (Scrip Code: 532815) has listed 50,00,000 new equity shares of Re. 1/- each on BSE, effective November 7, 2025. These shares were issued at a premium of Rs. 126/- to promoters on a preferential basis pursuant to conversion of warrants. The newly issued shares rank pari-passu with existing equity shares and are subject to a lock-in period until October 30, 2027.

Key Points

  • 50,00,000 equity shares of Re. 1/- each listed and permitted to trade from November 7, 2025
  • Issue price: Rs. 127/- per share (Re. 1/- face value + Rs. 126/- premium)
  • Issued to promoters on preferential basis through warrant conversion
  • Date of allotment: September 10, 2025
  • Distinctive numbers: 88652031 to 93652030
  • ISIN: INE812G01025
  • All shares subject to lock-in until October 30, 2027
  • New shares rank pari-passu with existing equity shares

Regulatory Changes

No regulatory changes introduced by this circular.

Compliance Requirements

  • Trading members are informed of the new securities listing
  • All 50 lakh shares are locked-in and cannot be transferred until October 30, 2027
  • Standard trading rules apply for these equity shares post lock-in expiry

Important Dates

  • Date of Allotment: September 10, 2025
  • Trading Commencement Date: November 7, 2025 (Friday)
  • Lock-in Expiry Date: October 30, 2027
  • Notice Date: November 6, 2025

Impact Assessment

Market Impact: Limited immediate impact as shares are issued to promoters and subject to a 2-year lock-in period. No free float increase until October 2027.

Shareholding Impact: Increases promoter holding through warrant conversion, strengthening promoter commitment to the company.

Liquidity Impact: Minimal near-term impact on trading liquidity as all shares are locked-in. Post lock-in, potential supply of 50 lakh shares may affect stock liquidity.

Capital Structure: Equity base expanded by 50 lakh shares with capital infusion of approximately Rs. 63.5 crores (at issue price of Rs. 127/-).

Impact Justification

Routine equity listing from warrant conversion with standard lock-in; limited immediate market impact as shares issued to promoters